PLASMINOGEN ACTIVATION IN HEALING HUMAN WOUNDS

被引:0
作者
SCHAFER, BM
MAIER, K
EICKHOFF, U
TODD, RF
KRAMER, MD
机构
[1] PHARMATEC GMBH,FRANKFURT,GERMANY
[2] ST JOSEF HOSP BOCHUM,CHIRURG ABT,BOCHUM,GERMANY
[3] UNIV MICHIGAN,MED CTR,DIV HEMATOL ONCOL,ANN ARBOR,MI
关键词
D O I
暂无
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Tissue injury is followed by formation of a provisional, fibrin-containing matrix. It is later on replaced by granulation tissue. Replacement involves extracellular proteolysis by fibrinolytic enzymes. Plasmin is a fibrinolytic proteinase and is generated from ubiquitous plasminogen by cell-derived urokinase-type (uPA) or tissue-type (tPA) plasminogen activator To explore the cells and components involved in plasminogen activation, we have performed a combined immunohistological and zymographic study on human skin wounds produced iatrogenically by debridement. The fibrin(ogen)-specific staining indicated the progressive removal of a fibrin-containing provisional matrix Plasmin(ogen) was present over the entire observation period It was diffusely distributed and also displayed a conspicuous association with cells of the granulation tissue, in particular with monocytes/macrophases and fibroblasts. Also, uPA was associated with monocytes/macrophages and fibroblasts, whereas the uPA-receptor (uPA-R) was stained in monocytes/macrophages only. The uPA was potentially active as indicated by zymography. No tPA-specific staining was found The findings point at the importance of monocytes/macrophages and fibroblasts in uPA-mediated plasminogen activation in healing human skin wounds.
引用
收藏
页码:1269 / 1280
页数:12
相关论文
共 45 条
[1]   PLASMINOGEN-ACTIVATOR INHIBITORS - HORMONALLY REGULATED SERPINS [J].
ANDREASEN, PA ;
GEORG, B ;
LUND, LR ;
RICCIO, A ;
STACEY, SN .
MOLECULAR AND CELLULAR ENDOCRINOLOGY, 1990, 68 (01) :1-19
[2]   CRYPTIC UROKINASE BINDING-SITES ON HUMAN FORESKIN FIBROBLASTS [J].
BAJPAI, A ;
BAKER, JB .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1985, 133 (02) :475-482
[3]   UROKINASE BINDING-SITES ON HUMAN FORESKIN CELLS - EVIDENCE FOR OCCUPANCY WITH ENDOGENOUS UROKINASE [J].
BAJPAI, A ;
BAKER, JB .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1985, 133 (03) :994-1000
[4]   THE RECEPTOR FOR UROKINASE-PLASMINOGEN ACTIVATOR [J].
BLASI, F ;
STOPPELLI, MP ;
CUBELLIS, MV .
JOURNAL OF CELLULAR BIOCHEMISTRY, 1986, 32 (03) :179-186
[5]   UROKINASE-TYPE PLASMINOGEN-ACTIVATOR - PROENZYME, RECEPTOR, AND INHIBITORS [J].
BLASI, F ;
VASSALLI, JD ;
DANO, K .
JOURNAL OF CELL BIOLOGY, 1987, 104 (04) :801-804
[6]  
BROWN LF, 1993, AM J PATHOL, V142, P273
[7]   MACROPHAGE FIBRINOLYTIC-ACTIVITY - IDENTIFICATION OF 2 PATHWAYS OF PLASMIN FORMATION BY INTACT-CELLS AND OF A PLASMINOGEN-ACTIVATOR INHIBITOR [J].
CHAPMAN, HA ;
VAVRIN, Z ;
HIBBS, JB .
CELL, 1982, 28 (03) :653-662
[8]  
Clark R.A.F., 1998, WOUND REPAIR MOL CEL, P3, DOI [10.1007/978-1-4615-1795-5_1, DOI 10.1007/978-1-4615-1795-5_1]
[9]   MOLECULAR MECHANISMS OF FIBRINOLYSIS AND THEIR APPLICATION TO FIBRIN-SPECIFIC THROMBOLYTIC THERAPY [J].
COLLEN, D .
JOURNAL OF CELLULAR BIOCHEMISTRY, 1987, 33 (02) :77-86
[10]   PLASMINOGEN ACTIVATORS, TISSUE DEGRADATION, AND CANCER [J].
DANO, K ;
ANDREASEN, PA ;
GRONDAHLHANSEN, J ;
KRISTENSEN, P ;
NIELSEN, LS ;
SKRIVER, L .
ADVANCES IN CANCER RESEARCH, 1985, 44 :139-266